Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology
研究报告     
The SARS-CoV 3a and 7a protein may enhance the induction of IFN-β
Download: HTML   PDF(0KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  3a and 7a are nonstructural proteins of SARS-CoV, which are encoded separately by ORF 3a and ORF 7a in SARS-CoV genome. The expression of 3a has been founded in cells infected by virus in vivo or in vitro. Firstly, the pGL3-Control vector was reconstructed , the pGL3-Enhancer vector deletious of SV40 promoter gene was obtained . Then the IFN-β promoter gene was cloned into the pGL3-Enhancer vector and pGL-IP21, the Luciferase reporter plasmid with IFN-β promoter was OK. The availability of pGL-IP21 was verified by NDV ,the inductor of IFN-β, the Luciferase activity was assayed in cells transfected with pGL-IP21 by Luminometer. In order to see the function of 3a and 7a protein of SARS-CoV,CHO cells expressing 3a or 7a protein were transfected with pGL-IP21, the intensity of luciferase activity was analyzed . By analysis, in vitro, 3a and 7a protein of SARS-CoV have the similar ability in triggering the expression of Luceferase gene, i.e 3a and 7a protein of SARS-CoV can effectively activate the promoter fragment of IFN-β gene. This result will help studying the function of 3a and 7a protein and provide a method to study the nosogenesis mechanism of SARS-CoV.

Key wordsSARS-CoV      3a protein      7a protein      IFN-β promoter      Luciferase Reporter System     
Received: 06 July 2006      Published: 25 December 2006
Cite this article:

. The SARS-CoV 3a and 7a protein may enhance the induction of IFN-β. China Biotechnology, 2006, 26(12): 6-10.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2006/V26/I12/6

[1] YUN Tao,GONG Yue,GU Peng,XU Bing-bing,LI Jin,ZHAO Xi-chen. Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19[J]. China Biotechnology, 2021, 41(7): 110-121.
[2] CHEN Chen,HU Jin-chao,CAO Shan-shan,MEN Dong. The Development of Antigen Testing for SARS-CoV-2[J]. China Biotechnology, 2021, 41(6): 119-128.
[3] SHI Rui,YAN Jing-hua. Research Progress of Neutralizing Antibody Drugs against SARS-CoV-2[J]. China Biotechnology, 2021, 41(6): 129-135.
[4] ZHANG Sai,WANG Gang,LIU Zhong-ming,LI Hui-jun,WANG Da-ming,QIAN Chun-gen. Development and Performance Evaluation of a Rapid Antigen Test for SARS-CoV-2[J]. China Biotechnology, 2021, 41(5): 27-34.
[5] FAN Yue-lei,WANG Yue,WANG Heng-zhe,LI Dan-dan,MAO Kai-yun. Research Progress of in Vitro Diagnostic Technologies for SARS-CoV-2[J]. China Biotechnology, 2021, 41(2/3): 150-161.
[6] WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.
[7] XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.
[8] PAN Tong-tong,CHEN Yong-ping. Research Progress of Key Techniques for Severe/Critical Type of Novel Coronavirus Pneumonia[J]. China Biotechnology, 2020, 40(1-2): 78-83.
[9] LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.
[10] LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing. Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2[J]. China Biotechnology, 2020, 40(12): 1-7.
[11] ZHU Yun-peng, WANG Peng, XIA Bo-ran, TANG Yan-ting, WANG Quan. Screening and Inhibition Kinetics of SARS Coronavirus Main Protease Inhibitors[J]. China Biotechnology, 2016, 36(4): 35-42.
[12] HU Hui, DAO Ling, CUI Bao-An, HUANG Yi, WANG Han-Zhong. Live-attenuated Salmonella typhimurium as a Oral Delivery Vehicle for SARS-CoV N DNA Vaccine[J]. China Biotechnology, 2010, 30(01): 41-46.